SecBot SecBot
Biotech Drug Report Generated Oct 31, 2026

Amlypave

AZN·ASTRAZENECA PLC
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved (Japan); Phase 3 completed globally
Time to market
Already approved and launched in Japan (September 2026) for kappa-type dominant AL amyloidosis. An EU marketing authorization application is under review by the EMA, but no specific decision date is specified. No US BLA filing has been filed in the US as of October 2026.
Why 3/10
No hard dated binary catalyst is scheduled in the next ~12 months: the Japan approval (September 2026) and the Phase 3 readout (May 2026) are past events. The EU marketing authorization review is ongoing but has no publicly specified decision date. For a mega-cap company like AstraZeneca, this single niche rare-disease drug is a small part of a vast pipeline, so even a positive or negative EU decision would not drive a major share-price move.
Actionable Insight NEUTRAL

Watch for the EU CHMP opinion and European Commission decision on the anselamimab marketing authorization application, which would open the European market. Watch for any US BLA filing announcement, which would create a new PDUFA catalyst. For now, the drug is already approved in Japan and the key binary readout (Phase 3) is past, so the stock-moving binary events are behind it for the near term.

Price Chart

Loading chart...

Executive Summary

Amlypave (anselamimab, formerly CAEL-101) is a first-in-class anti-fibril monoclonal antibody for AL amyloidosis, developed by AstraZeneca's Alexion unit. The global Phase 3 CARES program missed its primary endpoint in the overall population but showed a 62% survival benefit and 71% reduction in cardiovascular hospitalizations in a prespecified kappa light-chain subgroup. Japan approved the drug in September 2026 for kappa-dominant AL amyloidosis. An EU marketing authorization is under EMA review. For AstraZeneca, a $190B+ pharma giant, this is a niche rare-disease asset with a binary regulatory path still unfolding outside Japan.

How It Works

Amlypave is a monoclonal antibody (a lab-made immune protein) designed to recognize and latch onto misfolded amyloid fibrils -- abnormal protein clumps that build up in organs like the heart and kidneys in AL amyloidosis. Once bound, it flags them for the immune system's scavenger cells, which then clear the deposits. It is the first anti-fibril therapy, meaning it targets the amyloid deposits themselves rather than just the plasma cells producing the abnormal light-chain proteins.

Trial Status

The global CARES Phase III program (two parallel trials, CAEL101-301 and CAEL101-302, n=406) evaluated anselamimab added to standard-of-care plasma cell-directed therapy in patients with advanced (Mayo stage IIIa/IIIb) AL amyloidosis. The hierarchical composite primary endpoint of all-cause mortality and cardiovascular hospitalization was NOT met in the overall population (win ratio 1.11). However, a prespecified subgroup analysis of the kappa light-chain isotype subgroup (~17.7% of patients, ~72 patients) showed a 62% reduction in all-cause mortality and a 71% reduction in cardiovascular hospitalizations, with nominal statistical significance. Results were published in the Journal of Clinical Oncology and presented at ASCO 2026.

The Two-Sided Case

▲ Bull Case4
First-in-class anti-fibril mechanism that directly removes amyloid deposits, addressing a clear unmet need in AL amyloidosis where no approved therapy targets the fibrils themselves.
Japan approval in September 2026 provides a commercial foothold and regulatory validation for the kappa-subgroup strategy.
The kappa-subgroup data (62% survival improvement, 71% reduction in cardiovascular hospitalizations) is clinically meaningful and biologically plausible, and the drug was well-tolerated with a manageable safety profile.
EU marketing authorization application under EMA review could expand the addressable market beyond Japan.
▼ Bear Case4
The Phase 3 CARES program failed its primary endpoint in the overall AL amyloidosis population, a significant setback that limits the drug's addressable market to only kappa-type patients (~18% of patients).
The kappa subgroup benefit is based on only ~72 patients, a small sample that raises questions about robustness for broader regulatory approvals.
AstraZeneca is a mega-cap pharma giant (~$186/share, analyst consensus Buy with mean target of ~$206.66); this single drug is a minor pipeline asset in a company with dozens of approved drugs and hundreds of pipeline programs.
No US regulatory submission has been confirmed, and the path to FDA approval remains uncertain given the mixed Phase 3 results.

Upcoming Catalysts

  • EU CHMP opinion / European Commission decision on marketing authorization (no specific date available), potential US regulatory filing (if AstraZeneca pursues FDA submission for the kappa subgroup data)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ASTRAZENECA PLC 6-K AZN ·Originating report

Sources · 9

Hover a chip for the title
1 astrazeneca.com2 astrazeneca.com3 astrazeneca.com4 cancer.gov5 ascopubs.org6 indianpharmanetwork.in7 trademarks.justia.com8 ahajournals.org9 arci.org